Loading...
•
Sep 30, 2021
Roivant Sciences Q2 2022 Earnings Report
Roivant Sciences reported financial results for the quarter ended September 30, 2021 and provided a business update.
Key Takeaways
Roivant Sciences reported its financial results for the second fiscal quarter ended September 30, 2021. The company's cash and cash equivalents increased to $2.5 billion. Roivant closed its business combination with Montes Archimedes Acquisition Corp. and began trading on Nasdaq under the ticker "ROIV."
Roivant began trading on Nasdaq under “ROIV”; cash balance increased to $2.5 billion.
Dermavant announced final results from the Phase 3 PSOARING 3 long-term extension study of tapinarof in patients with plaque psoriasis (n=763).
Aruvant released clinical data from third and fourth patients dosed in ongoing Phase 1/2 trial of ARU-1801 in sickle cell disease, showing zero vaso-occlusive events 18 and 12 months after dosing, respectively
Roivant closed its business combination with Montes Archimedes Acquisition Corp. (“MAAC”) and concurrent PIPE financing, and Roivant began trading on Nasdaq under the ticker “ROIV.”
Roivant Sciences
Roivant Sciences
Forward Guidance
Roivant anticipates several milestones across its portfolio of companies. Dermavant expects an FDA decision on tapinarof for plaque psoriasis in Q2 2022 and topline data from a Phase 3 trial for atopic dermatitis in H1 2023. Immunovant plans to initiate a pivotal trial for batoclimab in myasthenia gravis in early 2022 and re-initiate programs in thyroid eye disease and warm autoimmune hemolytic anemia.
Positive Outlook
- Dermavant expects a decision from the FDA on the approval of tapinarof for the treatment of adults with plaque psoriasis in the second quarter of calendar year 2022.
- Dermavant expects to report topline data from Dermavant’s Phase 3 clinical trial of tapinarof for the treatment of atopic dermatitis in the first half of calendar year 2023.
- Immunovant plans to initiate a pivotal trial evaluating batoclimab for the treatment of myasthenia gravis in the early part of calendar year 2022.
- Immunovant plans to re-initiate its programs in thyroid eye disease and warm autoimmune hemolytic anemia.
- Aruvant is expected to report additional clinical data from its ongoing Phase 1/2 trial of ARU-1801 in sickle cell disease patients at ASH.